News
In total, 11 abstracts on givinostat were accepted for presentation at the Congress, including two for an oral presentation ...
Capricor Therapeutics's dip caused by the CRL is a buying opportunity considering the readout of HOPE-3 within 2-3 months.
A father of two sons diagnosed with muscular dystrophy is organizing a cornhole tournament this weekend to raise money for ...
MedPage Today on MSN10h
Duchenne Gene Therapy Will Undergo Changes After Patient DeathsAt the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...
New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular ...
The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment ...
News-Medical.Net on MSN1d
Targeting GLUD1 shows promise in restoring muscle function in Duchenne muscular dystrophyNew research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular ...
AI-based digital twin modeling predicts patient-specific decline, addressing key trial design and biomarker challenges in FSHD ...
The company said it was “surprised” by the decision, which followed the ouster of cell and gene therapy officials from the ...
InvestorsHub on MSN6d
Capricor Shares Tumble After FDA Rejects Duchenne Therapy ApplicationCapricor Therapeutics (NASDAQ:CAPR) saw its stock plummet by 53% on Friday after the U.S. Food and Drug Administration issued a Complete Response Letter (CRL), rejecting the company’s bid for approval ...
Norwegian documentary, The Remarkable Life of Ibelin, directed by Benjamin Ree, chronicles the life of Mats Steen, who had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback